Peptide Library

AHK-Cu is a copper-complexed tripeptide studied for potential effects on skin and tissue remodelling. Current evidence is primarily preclinical — mostly in vitro and animal studies — and clinical data are limited.

AOD-9604 is a synthetic peptide derived from the C‑terminal fragment of human growth hormone studied for effects on fat metabolism. Most evidence is preclinical; human data are limited and do not establish clinical benefit or long‑term safety.

ARA-290 (cibinetide) is a synthetic 11‑amino‑acid peptide derived from erythropoietin’s helix B. It is studied for tissue‑protective, anti‑inflammatory and neuroprotective effects, with most evidence from preclinical models and only limited, preliminary human data.

Adipotide is a synthetic, targeted proapoptotic peptide studied for reducing white adipose tissue by disrupting adipose vasculature. Evidence to date is preclinical: animal studies report fat loss and metabolic changes, but human data are lacking and safety concerns were…

B7-33 is a synthetic peptide derived from the B-chain of human relaxin-2. It is studied primarily in preclinical models for potential anti-fibrotic and tissue-remodelling effects; evidence remains limited to in vitro and animal studies.

BPC-157 is a 15–amino-acid peptide derived from a gastric juice protein fragment. It has been studied in preclinical models for tissue protection, wound and gastrointestinal healing, and angiogenesis, but evidence in humans is very limited and clinical efficacy remains unproven.

CJC-1295 is a synthetic growth hormone‑releasing hormone (GHRH) analogue developed to stimulate GH release and prolong circulating activity. It has been studied in animals and small human trials for effects on GH/IGF‑1 and related outcomes; evidence remains preliminary and…

Cagrilintide is an investigational long‑acting synthetic amylin analogue studied for weight management and metabolic effects. Evidence is emerging from preclinical work and early-phase human trials; longer-term efficacy and safety remain unestablished.

Delta sleep‑inducing peptide (DSIP) is a naturally occurring nonapeptide first identified in rabbit brain and studied for effects on sleep and stress-related neuroendocrine pathways. Current evidence is largely preclinical — animal and in vitro studies show biological activity,…

Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) studied for potential effects on cellular ageing and circadian regulation. Most evidence comes from cell and animal studies; clinical data are limited and preliminary.

FOXO4 refers to peptides engineered to interfere with the FOXO4–p53 interaction, most commonly the D‑retro‑inverso (DRI) FOXO4 peptide. It has been studied in cell and animal models for selective removal of senescent cells (senolysis); evidence remains at the preclinical stage…

Follistatin-344 is a naturally occurring 344–amino-acid isoform of follistatin that binds activins and myostatin. It has been studied primarily in preclinical models for effects on muscle growth, fibrosis, and metabolic regulation; human evidence remains very limited.

GHK-Cu is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) complexed with copper that has been studied for tissue repair, skin remodeling and anti-inflammatory effects. Current evidence is mainly preclinical with limited small topical or dermatologic reports;…

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic peptide studied for stimulating growth hormone secretion through the ghrelin receptor. Research is primarily preclinical with limited human data; clinical applications remain exploratory and evidence is incomplete.

GHRP-6 is a synthetic hexapeptide growth hormone secretagogue studied for stimulating GH release and influencing appetite. Research is largely preclinical with limited, small human studies; evidence for clinical benefit and safety remains incomplete.

Gonadorelin acetate is the synthetic form of native gonadotropin‑releasing hormone (GnRH). It is studied and used clinically to stimulate pituitary LH and FSH secretion for diagnostic testing and selected fertility indications; evidence is well established for diagnostic use but…

HGH Fragment 176-191 is a synthetic peptide derived from the C-terminal region of human growth hormone studied for potential metabolic and fat-loss effects. Available evidence is primarily preclinical (in vitro and animal), with limited and inconsistent human data and incomplete…

Hexarelin acetate is a synthetic hexapeptide ghrelin receptor agonist studied for growth hormone release and potential cardioprotective effects. Available evidence is mainly preclinical, with limited short-term human pharmacology studies and insufficient data for clinical use.

Humanin is a small mitochondrial-derived peptide studied for cytoprotective, neuroprotective and metabolic effects. Research comes predominantly from cellular and animal models; human data are limited and exploratory.

IGF-1 LR3 is a laboratory-modified, long-acting analogue of human IGF-1 studied for tissue growth, regeneration and metabolic effects. Evidence is primarily preclinical — mostly cell and animal studies — with limited human data and notable safety uncertainties.

Ipamorelin is a synthetic pentapeptide that acts as a selective ghrelin (GHSR) receptor agonist. It has been studied primarily for its ability to stimulate growth hormone (GH) secretion; current evidence is largely preclinical with limited early human data.

KPV (Lys‑Pro‑Val) is a naturally occurring tripeptide derived from the C‑terminus of alpha‑MSH studied for anti‑inflammatory and mucosal protective effects. Current evidence is largely preclinical: cell and animal studies report immunomodulatory activity, while human data are…

Kisspeptin‑10 is a decapeptide fragment of the kisspeptin family that activates the KISS1R (GPR54) receptor. It is studied primarily as a probe of hypothalamic–pituitary–gonadal axis function and short‑term gonadotropin stimulation; evidence is largely preclinical with early…

LL-37 is a human-derived cathelicidin antimicrobial peptide studied for antimicrobial, immunomodulatory, and wound-hepair activities. Most evidence is preclinical; clinical investigation is limited and exploratory.

Liraglutide is a synthetic, acylated analogue of human GLP-1 studied and used to improve glycemic control and reduce body weight. It has substantial clinical trial evidence for type 2 diabetes and obesity, though ongoing studies address long-term outcomes and safety nuances.

MOTS-C is a mitochondrial-derived 16–amino-acid peptide studied for metabolic regulation, insulin sensitivity, and mitochondrial signalling. Evidence is predominantly preclinical, with limited and inconsistent human observational data.

Mazdutide is a synthetic, peptide-based GLP-1 receptor agonist candidate studied for weight reduction and glycaemic control. Evidence is preliminary, coming mainly from preclinical work and limited early human studies.

Melanotan I (afamelanotide) is a synthetic analogue of α‑MSH studied for increasing skin eumelanin and reducing photosensitivity. Clinical trials support its use for erythropoietic protoporphyria (EPP), but evidence for broader cosmetic or photoprotective use is limited and…

Melanotan II (MT-2) is a synthetic cyclic peptide analogue of α‑MSH studied for skin pigmentation and related melanocortin effects. Research is limited and heterogeneous; safety, long-term outcomes, and standardized clinical use remain incompletely characterised.

NAD+ (nicotinamide adenine dinucleotide) is a central cellular coenzyme involved in redox reactions and as a substrate for signalling enzymes. It is studied for roles in metabolism, mitochondrial function and age-related decline; most evidence is preclinical with emerging, limited human data.

Oxytocin acetate is the acetate salt form of oxytocin, a nine‑amino‑acid neuropeptide studied for childbirth, lactation, social bonding and stress modulation. Established obstetric uses exist, while research into behavioural and neuropsychiatric applications is emerging and…

P21 is a short synthetic peptide studied in preclinical research for effects on cell signalling, migration, and tissue repair. Available evidence is limited to in vitro and animal studies; clinical relevance and safety in humans are not established.

PE-22-28 is a short synthetic heptapeptide studied in preclinical research for potential effects on tissue repair, inflammation, and extracellular matrix dynamics. Current evidence is limited to in vitro and animal studies; clinical data are absent.

Bremelanotide (PT-141) is a synthetic cyclic melanocortin receptor agonist studied for sexual desire and arousal. Clinical trials support short-term benefits in some people with hypoactive sexual desire, but long‑term safety and broader effectiveness remain under study.

Pinealon is a small peptide originally associated with pineal gland peptides and studied for neuroprotective and cognitive-supportive effects. Evidence is primarily preclinical—mainly cell and animal studies—with limited and low-quality human data.

Retatrutide is a synthetic, engineered peptide acting on multiple metabolic receptors. It is being studied primarily for weight loss and metabolic improvement in clinical trials. Early clinical data are promising, but longer-term efficacy and safety remain under investigation.

SS-31 (elamipretide) is a synthetic mitochondria-targeting tetrapeptide studied for mitochondrial protection and oxidative stress modulation. Most supporting data are from cellular and animal studies; human evidence is limited and mixed.

Selank is a synthetic heptapeptide developed as an analog of the immune peptide tuftsin. It has been studied for potential anxiolytic, cognitive and immunomodulatory effects, but evidence remains mostly preclinical with limited, small clinical reports.

Semaglutide is a synthetic GLP‑1 receptor agonist peptide studied and used for type 2 diabetes and chronic weight management. Clinical evidence from multiple randomized trials supports effects on glycemic control and weight, though long‑term real‑world safety and…

Semax is a synthetic heptapeptide analogue of the ACTH(4–10) fragment studied for potential neuroprotective and cognitive-supporting effects. Most evidence is preclinical with a limited number of small clinical studies, so clinical efficacy remains preliminary.

Sermorelin is a synthetic 29–amino-acid analogue of growth hormone–releasing hormone (GHRH) that stimulates endogenous growth hormone (GH) secretion. It has clinical study support for pediatric GH deficiency, while evidence for adult anti‑aging or performance uses remains…

Snap-8 is an acetylated octapeptide derived from the SNAP-25 protein, developed for topical cosmetic use to modulate dynamic facial lines. Evidence is preliminary and comes mainly from in vitro work, ex vivo skin tests, and small cosmetic trials, so clinical benefits remain…

Survodutide is an investigational synthetic peptide being studied for metabolic regulation, including appetite and glucose control. Available evidence is primarily preclinical and limited; clinical safety and efficacy remain unestablished.

TB-500 is a synthetic peptide fragment modeled on thymosin beta‑4 and investigated for effects on tissue repair, cell migration, and angiogenesis. Current evidence is mainly preclinical; human clinical data are limited and insufficient to establish safety or efficacy.

Teriparatide is a recombinant fragment (1–34) of human parathyroid hormone studied and used as an anabolic agent for bone. Clinical trials and regulatory approvals support its use to increase bone formation and reduce vertebral fractures, though treatment duration and long-term…

Tesamorelin is a synthetic growth‑hormone‑releasing hormone (GHRH) analogue studied primarily to reduce visceral adipose tissue. Clinical trials support its use for HIV‑associated lipodystrophy, while evidence for other indications remains limited and under investigation.

Thymalin is a thymus-derived low-molecular-weight peptide complex studied for immune modulation and support of thymic function. Most evidence is preclinical or from small, older clinical reports; robust, modern clinical trials are limited.

Thymosin alpha-1 (TA1) is a 28‑amino‑acid thymic peptide studied for immune modulation. Research explores antiviral, adjuvant, and immunorestorative uses; evidence is largely preclinical with limited and heterogeneous human data.

Thymulin is a zinc‑dependent nonapeptide produced by thymic epithelial cells, studied for immune development and neuroendocrine effects. Research is largely preclinical, with limited and inconsistent human data; clinical relevance remains uncertain.

Tirzepatide is a synthetic dual GIP and GLP-1 receptor agonist studied for type 2 diabetes and obesity. Phase 3 clinical trials report improved glycaemic control and substantial weight loss compared with some comparators. Evidence is clinical and expanding, though longer-term…

Vasoactive intestinal peptide (VIP) is a 28‑amino‑acid neuropeptide studied for vasodilation, bronchodilation, and immune modulation. Current evidence is mainly preclinical with limited and variable early clinical investigations.